Your browser doesn't support javascript.
loading
SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis.
Kelly, J Daniel; Curteis, Tristan; Rawal, Aaditya; Murton, Molly; Clark, Laura J; Jafry, Zarena; Shah-Gupta, Rikisha; Berry, Mark; Espinueva, Aprille; Chen, Linda; Abdelghany, Mazin; Sweeney, Daniel A; Quint, Jennifer K.
Afiliação
  • Kelly JD; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA Dan.Kelly@ucsf.edu.
  • Curteis T; Costello Medical Consulting Ltd, Manchester, UK.
  • Rawal A; Costello Medical Consulting, Inc., Boston, MA, USA.
  • Murton M; Costello Medical Consulting Ltd, London, UK.
  • Clark LJ; Costello Medical Consulting Ltd, Manchester, UK.
  • Jafry Z; Costello Medical Consulting, Inc., Boston, MA, USA.
  • Shah-Gupta R; Gilead Sciences Europe Ltd, Uxbridge, UK.
  • Berry M; Gilead Sciences Europe Ltd, Uxbridge, UK.
  • Espinueva A; Gilead Sciences, Inc., Foster City, CA, USA.
  • Chen L; Gilead Sciences, Inc., Foster City, CA, USA.
  • Abdelghany M; Gilead Sciences, Inc., Foster City, CA, USA.
  • Sweeney DA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of California, San Diego, CA, USA.
  • Quint JK; School of Public Health and National Heart and Lung Institute, Imperial College London, London, UK.
Eur Respir Rev ; 32(169)2023 Sep 30.
Article em En | MEDLINE | ID: mdl-37437914
ABSTRACT

BACKGROUND:

Many individuals hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection experience post-acute sequelae of SARS-CoV-2 infection (PASC), sometimes referred to as "long COVID". Our objective was to conduct a systematic literature review and meta-analysis to identify PASC-associated symptoms in previously hospitalised patients and determine the frequency and temporal nature of PASC.

METHODS:

Searches of MEDLINE, Embase, Cochrane Library (2019-2021), World Health Organization International Clinical Trials Registry Platform and reference lists were performed from November to December 2021. Articles were assessed by two reviewers against eligibility criteria and a risk of bias tool. Symptom data were synthesised by random effects meta-analyses.

RESULTS:

Of 6942 records, 52 studies with at least 100 patients were analysed; ∼70% were Europe-based studies. Most data were from the first wave of the pandemic. PASC symptoms were analysed from 28 days after hospital discharge. At 1-4 months post-acute SARS-CoV-2 infection, the most frequent individual symptoms were fatigue (29.3% (95% CI 20.1-40.6%)) and dyspnoea (19.6% (95% CI 12.8-28.7%)). Many patients experienced at least one symptom at 4-8 months (73.1% (95% CI 44.2-90.3%)) and 8-12 months (75.0% (95% CI 56.4-87.4%)).

CONCLUSIONS:

A wide spectrum of persistent PASC-associated symptoms were reported over the 1-year follow-up period in a significant proportion of participants. Further research is needed to better define PASC duration and determine whether factors such as disease severity, vaccination and treatments have an impact on PASC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article